Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
|Videos|April 13, 2022
The Hidden Costs of Atopic Dermatitis
Author(s)Miranda Hester
Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research expands on her talk from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is held from April 9 to 11 in Baltimore, Maryland.
Advertisement
Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research, describes how the costs of eczema for many family is beyond medication expenses.
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
2
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
3
GLP-1 Candidacy and Prescribing Considerations in Psoriasis
4
JAK Inhibitors for Alopecia Areata: Selectivity and Pivotal Trial Efficacy
5